Terminé

Accuracy of SPD Persona LH Assay When Compared to Ultrasound Observed Ovulation and Other Indices of Ovulation

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est collecté

Collecte de données

Données recueillies dès le début de l'étude - Prospective
Sans prélèvements ADN
Qui peut participer

De 18 à 40 ans
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Cohorte

Suivi d'un groupe de personnes dans le temps pour mieux comprendre les causes et l'évolution d'une maladie.
Observationnel
Date de début : février 2013
Voir le détail du protocole

Résumé

Sponsor principalSPD Development Company Limited
Dernière mise à jour : 2 décembre 2014
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 1 février 2013

Date à laquelle le premier participant a commencé l'étude.

Persona is a CE marked, natural method of contraception that works by monitoring hormone changes in a woman's urine to identify the days of her menstrual cycle when she is likely to become pregnant following unprotected intercourse. Persona consists of test sticks that measure luteinising hormone (LH) and estrone-3-glucuronide (E3G), which are read by a handheld monitor. This hormonal data is converted using a proprietary algorithm, into simple-to-understand information on the user's contraceptive status; a "red light" where she needs to abstain from intercourse to avoid pregnancy, or a "green light" where unprotected intercourse is unlikely to lead to pregnancy. A prospective 13 cycle reliability study has found Persona to be 94% effective. This study will examine the relationship between the information provided by the Persona assays and ultrasound observed ovulation, along with other indicators of when a woman is fertile (basal body temperature (BBT) measurement and cervical secretion observations). This is a single centre clinical study which will be conducted at the green-ivf clinic in Grevenbroich, Germany. The primary objective will be to assess the difference between the timing of the LH surge detected by Persona and observed ovulation by reference to transvaginal ultrasound examination. In addition, comparison of Persona determined levels of LH and E3G will be made to urine and serum levels of these and other reproductive hormones. Comparison will also be made to BBT and cervical secretion observations which are indirect measurements of the fertile phase. In order to achieve these objectives, a minimum of 40 female volunteers will be recruited by the study site either out of the patient pool coming for routine gynaecological examination or from the general population via newspaper advertisement. The study will last for one menstrual cycle starting on the first day of menstrual bleeding (day 1 of the cycle) and concluding with the onset of the next menses. Volunteers will be asked to collect daily urine samples and use an adapted Persona monitor for the duration of the study as per the first cycle of use (i.e. a maximum of 16 tests). The monitor will be adapted to blind the user from the result of each test. Volunteers will therefore be advised that the modified Persona monitor cannot be used as a contraceptive device during the study. Volunteers will also be asked to take daily measurements of BBT and to record this along with cervical secretion observations on a daily natural family planning (NFP) chart. Volunteers will be required to attend for a recruitment visit to the trial site followed by approximately 12 visits either daily, or two days apart. Transvaginal ultrasonography will be carried out on cycle days 5, 7, 9, 11 and daily from 16mm follicular size onwards until ovulation has occurred. Blood sampling will also be conducted on these days as well as on day 7 and day 9 post-ovulation. Ultrasound examinations, blood sampling and hormonal blood tests will be performed at the trial centre. Urine samples will be shipped to the study sponsor for hormonal analysis. Diary and scan data will also be transferred to the study sponsor to provide a single data set for analysis.

Sponsor principalSPD Development Company Limited
Dernière mise à jour : 2 décembre 2014
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

51 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Cohorte

Ce type d'étude observe, sur une période définie, un groupe de personnes partageant une caractéristique commune (comme une maladie ou une année de naissance), afin d'analyser leur état de santé ou leur exposition à certains facteurs.


Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Critères

Femme

Le sexe biologique des participants éligibles à s'inscrire.

De 18 à 40 ans

Tranche d'âge des participants éligibles à participer.

Volontaires sains autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Critères

Inclusion Criteria: Female Aged 18 - 40 years Menstrual cycle length between 23 and 35 days Had two natural cycles prior to study participation Using non-hormonal contraception to avoid pregnancy OR abstaining from intercourse for the last three months and the present cycle N.B: Non hormonal contraception includes barrier methods such as male and female condoms, diaphragms or caps, non-hormonal intra-uterine devices such as coils, male and female sterilisation or natural family planning Exclusion Criteria: Unwilling to provide written informed consent to participate in the study or comply with study procedures Pregnant Breastfeeding Has menopausal symptoms such as night sweats or hot flushes Using any hormonal treatments e.g. hormonal contraception, fertility treatments and hormone replacement therapy (except thyroxin) Taking antibiotics (based on decision by principle investigator) Has a diagnosis of polycystic ovarian syndrome (PCOS) Has impaired liver or kidney function Intending to use PERSONA as a contraceptive during the study period Contraindications to frequent blood sampling e.g. anaemia, hypotonia and blood clotting diseases Contraindications to frequent ultrasound examinations e.g. morbid obesity and recent abdominal surgery

Plan de l'étude

Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.
Objectifs de l'étude

Objectifs de l'étude

Objectifs principaux

Objectifs secondaires

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

Green-ivf, Rheydter Strasse 143, Grevenboich

Düsseldorf, GermanyOuvrir Green-ivf, Rheydter Strasse 143, Grevenboich dans Google Maps
Terminé1 Centres d'Étude